Monoclonal antibodies as therapeutics in human malignancies

Manjari Pandey, Daruka Mahadevan

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations

Abstract

Monoclonal antibodies (mAbs) are a proven effective therapeutic modality in human malignancy. Several mAbs are approved to targets critical in aberrant oncogenic signaling within tumors and their microenvironment. These targets include secreted ligands (e.g., VEGF and HGH), their receptors (e.g., HER2 and VEGFR2), cell surface counter receptors and their receptor-bound ligands (e.g., PD1 and PD1L, respectively). The ability to genetically engineer the structure and/or functions of mAbs has significantly improved their effectiveness. Furthermore, advances in gene expression profiling, proteomics, deep sequencing and deciphering of complex signaling networks have revealed novel therapeutic targets. We review target selection, approved indications and the rationale for mAb utilization in solid and hematologic malignancies. We also discuss novel mAbs in early- and late-phase clinical trials that are likely to change the natural history of disease and improve survival. The future challenge is to design mAb-based novel trial designs for diagnostics and therapeutics for human malignancies.

Original languageEnglish (US)
Pages (from-to)609-636
Number of pages28
JournalFuture Oncology
Volume10
Issue number4
DOIs
StatePublished - Mar 2014
Externally publishedYes

Keywords

  • antibody drug conjugates
  • antibody engineering
  • antibody targets
  • clinical trials
  • monoclonal antibodies
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Monoclonal antibodies as therapeutics in human malignancies'. Together they form a unique fingerprint.

Cite this